Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 417-310-0 | CAS number: 72903-27-6
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
The substance has no harmonized toxicological classification. No adverse effects have been observed in studies at the highest recommended dose tested:
- 1000 mg/kg bw/day, in a sub-acute toxicity study by oral route (OECD 407, GLP)
- 1000 mg/kg bw.day, in a sub-chronic toxicity study by oral route (OECD 408, GLP) conducted on the supporting substance, 1,4-cyclohexanedicarboxylic acid;
- Equivalent to 888 mg/kg bw/day (males) and to 1124 mg/kg bw/day (females) (achieved dose), in a reproduction/developmental screening study conducted on an analogue substance (OECD 421, GLP);
Moreover, tests assessing the mutagenic potential of the substance in vitro provided no evidence of mutagenic or genotoxic activity.
Indications of toxicity to reproduction and development were not observed in a reproduction/developmental toxicity screening test conducted on an analogue substance.
As no adverse effects have been observed for any of the relevant human heath endpoints, no DNEL can be derived. Hence, exposure assessment of workers is not needed.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The substance has no harmonized toxicological classification. No adverse effects have been observed in studies at the highest recommended dose tested:
- 1000 mg/kg bw/day, in a sub-acute toxicity study by oral route (OECD 407, GLP)
- 1000 mg/kg bw.day, in a sub-chronic toxicity study by oral route (OECD 408, GLP) conducted on the supporting substance,1,4-cyclohexanedicarboxylic acid;
- Equivalent to 888 mg/kg bw/day (males) and to 1124 mg/kg bw/day (females) (achieved dose), in a reproduction/developmental screening study conducted on an analogue substance (OECD 421, GLP);
Moreover, tests assessing the mutagenic potential of the substance in vitro provided no evidence of mutagenic or genotoxic activity.
Indications of toxicity to reproduction and development were not observed in a reproduction/developmental toxicity screening test conducted on an analogue substance.
As no adverse effects have been observed for any of the relevant human heath endpoint, no DNEL can be derived. Hence, exposure assessments of consumers and humans exposed via the environment are not needed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
